Geron Corp (GERN)

I see this has come off of its lows again . I wonder how many more people this will suck in and go nowhere like it has for 25 years . This company is pathetic

Seems like it’s all about patent protection at this point? Any thoughts?

Up a nickel in pre-market, hope that is the sign of the day..

Earnings better

Grrrron…Moving at the speed of a 90 year old grandma. Come on already!!!

Something is going on, 39.1 million shares traded today. this is the highest total I can recall.

Good call. EU is a challenge. I wish they had addressed expansion into other disease settings.

https://edge.media-server.com/mmc/p/i6bmvewz/

Geron shares drop after Q4 results miss estimates despite Rytelo growthFebruary 25, 2026 10:39 AM
IH Market News
Geron Corporation (NASDAQ:GERN) shares fell roughly 15% in premarket trading Wednesday after the oncology-focused biotech company reported fourth-quarter 2025 results that came in below Wall Street expectations while reaffirming its full-year guidance.The developer of blood cancer treatment Rytelo posted a net loss of $0.05 per share on revenue of $48.0 million for the quarter, missing analyst forecasts by more than $2.4 million as revenue remained largely unchanged sequentially.For the full year, total costs and operating expenses increased about 2% year over year to $254.7 million. Fourth-quarter net loss widened approximately 23% compared with the prior year period to $31.1 million, reflecting a $17.0 million restructuring charge tied to a cost-reduction program launched in December.Despite the quarterly miss, full-year revenue more than doubled to $183.9 million, supported by the June 2024 U.S. Food and Drug Administration approval of Rytelo for treating myelodysplastic syndromes, a rare form of blood cancer.Net product revenue from Rytelo reached $48 million during the quarter, representing roughly 9% growth from the third quarter and bringing full-year net product revenue to $183.6 million.Looking ahead, Geron maintained its outlook, forecasting full-year net product revenue for Rytelo in the range of $220 million to $240 million, alongside projected operating expenses of $230 million to $240 million.Geron Corporation stock price

Original: Geron shares drop after Q4 results miss estimates despite Rytelo growth

I have a great idea let’s give it another 30 years. What a joke !

Well, it's been a real roller coaster recently. Tomorrow I think we'll know we're this might be going.

Geron Plans to Present at Upcoming Investor Conferences

February 23, 2026
PDF Version
FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences:

TD Cowen 46th Annual Healthcare Conference
Fireside Chat on Monday, March 2 at 1:10 p.m. ET in Boston, MA

Barclays 28th Annual Global Healthcare Conference
Fireside Chat on Tuesday, March 10 at 10:30 a.m. ET in Miami, FL

Leerink Partners Global Healthcare Conference
In-Person Meetings on Wednesday, March 11 in Miami, FL
A live and archived audio webcast of each fireside chat will be available through the Investors & Media section of Geron’s website at www.geron.com.

GERN will be presenting at 3 conferences in March, on the 2nd, 10th and 11th!

February 11, 2026
FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth quarter and full year 2025 financial results and business highlights before the market opens on Wednesday, February 25, 2026 via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.

Feb 25, Q4 will be released, YOY rev is going to be HUGE! Hopefully, this news will get a lot of new eyes on GERN. Looking for 2026 to be a banner year from a company growth and stonk price prospective! LG

looking great, but  buy the rumor sell the news ?looking great, but  buy the rumor sell the news ?

I have owned and traded GERN since 2013, just after the Mayo Clinic results were released. It has been a wild ride, but an extremely profitable one for me...glad I was accumulating below $1.20 a few weeks ago, today was confirmation that it was a gift at those low levels. Can't wait to see this name really squeeze the shorts who have controlled it for many years...imo, again 2026 should be a stellar for GERN shareholders...LG! GLTA!

Dapper1
Re: None
Wednesday, December 17, 2025 10:19:09 PM
Post# of 8025
GERN, saw some heavy volume and a nice 4.5% up tick in a very red market today! IMO, in 2026 we should see the stock price much higher. LG
Bullish

another 1 million in 1/2 hour in after hours

Someone knows something that we. About 26M of them

Where's the news?

Good for you . There is a corrupt reason for this company being where it is . I just cannot figure out what that is .

Sold all but 500 shares early in the month and bought silver....as of today made up all of my losses in Geron plus some.

What a fucking broken record this company is

HEAVY VOLUME 18M @ 2PM and almost 10% increase. If tomorrow follows today instead of retreating like it has in the past, something may be up.

If it doesn’t show that anything is happening with 4th quarter results forget it it is over .

GERN, saw some heavy volume and a nice 4.5% up tick in a very red market today! IMO, in 2026 we should see the stock price much higher. LG

Seems like the right move? My sense was they had a lot of redundancy. But I hope this doesn’t mean they’re not expanding into other diseases?

https://www.globenewswire.com/news-release/2025/12/11/3203827/35501/en/Geron-Corporation-Announces-Strategic-Restructuring-Plan-to-Position-the-Company-for-Long-Term-Value-Creation.html

https://ih.advfn.com/p.php?pid=nmona&article=97379789&_gl=1*aqkh71*_gcl_au*Mzg0Mjk1ODk4LjE3NTkwMzMzNjEuNjAyMzg0MjczLjE3NjM0MDYzODAuMTc2MzQwNjM4MQ..

It’s been a long and painful road with this one, no doubt about it. But as long as they keep that blurb in the filings about not needing to dilute anymore, I’m waiting for better days.

It’s just been ridiculous. How many years do investors have to wait . I wish you the best of luck , I just could not wait any longer

>>Regarding the EU, we remain excited. I mean, we do have an approval in the EU, which really sets us apart. We are very excited about that. We want to make sure that we are good stewards for our investments. That is where the focus at this point of our own internal efforts are on the U.S., obviously, for two reasons: U.S. being the largest market, but also the fact that iMERG has had a much more robust usage in Europe rather than in the U.S.

Geron Shrinks Quarterly Losses And Meets Revenue Goals

>>Geron’s Q3 2025 update paints a picture of a company making real progress. Revenue reached $47.2 million, driven almost entirely by RYTELO, though overall demand dipped 3% year-on-year. Net losses improved to $18.4 million from $26.4 million last year, while earnings per share came in at -$0.03. Operating loss was also better than expected, landing at $13.88 million versus analysts’ forecasts of $17.30 million. With annual expenses projected to hit up to $260 million, Geron’s focus is on maintaining RYTELO sales and reining in costs. Looking ahead, investors are eyeing data from the IMpactMF trial, with a key readout due in late 2026.

>> Geron’s path highlights a growing trend in biotech, where consistent drug launches and solid cost control spark confidence even ahead of big clinical milestones. With financial discipline and targeted therapies keeping companies afloat, Geron’s progress is one more signpost for the sector’s evolving playbook.


https://finimize.com/content/geron-shrinks-quarterly-losses-and-meets-revenue-goals

>>Outlook & Guidance
Geron has revised its full-year 2025 operating expense guidance downward to $250-$260 million from the previous $270-$285 million, signaling efforts to manage costs effectively. Looking ahead, the company is positioning 2026 as a growth year, with plans to expand Rytelo’s market reach and prepare for European commercialization.

>> During the quarter, demand for Rytelo was down 3% compared to last quarter. New patient starts in first and second line increased to 36% compared to 30% in Q2. However, new patient starts did not offset the discontinuations we saw from patients using Rytelo in later line. It is clear we have work to do on establishing Rytelo as a second-line therapy in eligible patients with low-risk MDS and educating HCPs on treatment management. Prescribing accounts increased by 15% in the quarter, with approximately 150 new ordering accounts added in Q3, expanding our footprint to 1,150 accounts. Lastly, we completed the first shipment of Rytelo to Germany under a named patient early access program. We’re preparing for the planned commercialization of Rytelo in select European Union markets in 2026.

https://www.investing.com/news/transcripts/earnings-call-transcript-geron-q3-2025-reveals-revenue-miss-stock-dips-93CH-4333851

Well it is official this company is done RS coming soon . Waited a long time for this to do something but it will not . Lost a lot of money in this one but it has been 7 years so it softens the blow

Earnings... stock dismal.. not adding 

Gonna have to give the new CEO and his team a little more time probably. We need EU sales.

>>In other recent news, Geron Corporation reported its first-quarter 2025 earnings, meeting analysts’ expectations with an earnings per share (EPS) of -0.03. However, the company’s revenue fell short of projections, coming in at $39.6 million compared to the anticipated $50.46 million. The company’s stockholders approved amendments to its equity incentive and employee stock purchase plans, increasing the share reserve, which reflects Geron’s strategy to incentivize and retain employees. Additionally, Geron presented new data on its drug RYTELO® at major oncology conferences, highlighting its efficacy in treating lower-risk myelodysplastic syndromes (LR-MDS) and progress in myelofibrosis trials.
Geron is also focusing on the commercialization of RYTELO, which saw a 10% demand increase in April, and is expanding its commercial field team to enhance market penetration. The company is preparing for potential launches in selected European countries by 2026. Furthermore, Geron’s ongoing trials, including IMpactMF, are exploring the potential of imetelstat, RYTELO’s active ingredient, for treating myelofibrosis, with preliminary data indicating promising results. Despite the revenue miss, the company maintains a strong cash position with $457.5 million in cash and equivalents as of the end of the first quarter. These developments underscore Geron’s strategic efforts to address market challenges and explore new growth opportunities.

>>FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the course of cancer, today announced that it will release its third quarter financial results and business highlights before the market opens on Wednesday, November 5, 2025 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.

Q3 on deck . This is the watershed moment for gern. If they do not start showing that they have improved with sales revenue etc . And most of all management showing that they want this company to succeed. If it drops after results you will see a RS shorty after .

$GERN "According to the latest SEC 13F filing for Q2 2025 (ended June 30, 2025), Aberdeen Group plc increased its holdings in Geron Corporation (NASDAQ: GERN) by 89.2%, adding 3,293,179 shares to reach a total of 6,985,932 shares (approximately 6.99 million). At the quarter-end share price of about $1.41, this stake was valued at roughly $9,850,000 (nearly $9.85 million). This data is confirmed in financial reports summarizing institutional ownership changes."

No surprise, that is commonly done at executive level...CEO needs to bring in new peeps he knows and can trust.

The new CEO is shaking things up a bit bringing in his people.

https://ir.geron.com/investors/press-releases/press-release-details/2025/Geron-Corporation-Announces-Executive-Leadership-Transitions-and-Appointments/default.aspx

A director picked up 5,702 shares in lieu of cash compensation.👍. It’s a start.

GERN - Look for more upside this month and some serious FOMO buying in early November!

😪 You should short it and find out!

1 month away from due or die . November 6th is it if they don’t give companies reason to look at buying them they will not make it on their own . So sad

Nice. Something tells me this CEO wants to go out with a bang!

https://oncodaily.com/career/harout-semerjian

Even the idiots on this board cannot defend this shit anymore . It is so sad how management destroyed what could have been a great investment

Wow … total garbage!

For what it’s worth.

>>Valuation Analysis: A Discounted Opportunity
Despite RYTELO’s growth and pipeline progress, GERN
GERN
-1.43%
trades at a P/S ratio of 5.4x, well below its peer average of 6.5x and the biotech industry average of 8.7x [3]. This discount reflects the market’s skepticism about RYTELO’s long-term potential and the company’s current net loss position (P/E of -10.77) [4]. However, the stock is trading well below its estimated fair value of $12.71, creating a compelling risk/reward profile.

Analyst price targets further underscore this imbalance. The average target of $3.63 implies a 159% upside from the current price of $1.40, with some estimates as high as $9.00 [3]. While these targets are optimistic, they align with RYTELO’s market expansion and the completion of the IMpactMF trial.

https://www.ainvest.com/news/geron-corporation-gern-high-conviction-buy-strong-q2-results-2508/

Well this better have great actually tremendous third quarter sales or kiss this goodbye . The only chance this has is a buyout and that will not happen unless sales explode

Mystifying the level of retail research contributions and opinion on the NWBO iHub board as compared to a stock like GERN that’s still cheap and has everything going for it??

🤣 okay big talker!
I loaded the boat the morning news hit the wire that JNJ pulled the plug...also, I made a ton trading GERN after the Mayo Clinic news was released back in 2013.
Too bad you're underwater, hence why you're a disgruntled shareholder. Keep holding, you'll get whole again, but it may take a few Qs.
Long & Strong GERN